Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company based in Perth, Australia. The company specializes in developing and commercializing products for the repair and regeneration of damaged nerves, with its flagship product being Remplir™, a collagen wrap used in nerve repair surgery. Orthocell operates in a global market with approvals in the US, Australia, New Zealand, Singapore, and now Thailand, targeting a large addressable nerve repair market.
YTD Price Performance: -4.80%
Average Trading Volume: 1,556,206
Technical Sentiment Signal: Sell
Current Market Cap: A$312.1M
Learn more about OCC stock on TipRanks’ Stock Analysis page.